# Entrada Therapeutics (TRDA) — News

TRDA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/trda/news

## Recent headlines

- [Entra decided to start share buyback program of up to NOK 200M](https://www.ainvest.com/news/entra-decided-start-share-buyback-program-nok-200m-2610) — AInvest Wire, Oct 15, 2026
- [Entra 3Q net oper income NOK 709M, est. NOK 714M](https://www.ainvest.com/news/entra-3q-net-oper-income-nok-709m-est-nok-714m-2610) — AInvest Wire, Oct 15, 2026
- [Entra 3Q net loss NOK 450.0M, est. profit NOK 268M](https://www.ainvest.com/news/entra-3q-net-loss-nok-450-0m-est-profit-nok-268m-2610) — AInvest Wire, Oct 15, 2026
  Entra reported a net loss of NOK 450.0 million for the third quarter, significantly below the estimated profit of NOK 268 million. This outcome contrasts with the broader performance of the technology sector, where Microsoft, for example, reported strong results in its third quarter of fiscal 2023,…
- [Entra 3Q rental income NOK 782M est. NOK 778.8M](https://www.ainvest.com/news/entra-3q-rental-income-nok-782m-est-nok-778-8m-2610) — AInvest Wire, Oct 15, 2026
- [Entrada Therapeutics - Elevate-45-201 cohort 2 enrollment complete; data at 10 mg/kg expected first half 2027](https://www.ainvest.com/news/entrada-therapeutics-elevate-45-201-cohort-2-enrollment-complete-data-10-mg-kg-expected-2027-2610) — AInvest Wire, Oct 14, 2026
  Entrada Therapeutics has announced that enrollment for Cohort 2 of its ELEVATE-45-201 clinical trial has been completed. This trial is part of the company’s ongoing efforts to develop exon-skipping therapies for Duchenne muscular dystrophy (DMD) in patients amenable to exon 45 skipping. The cohort…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).